Skip to main content
OpenTrials

Clinical trial condition

Progesterone Receptor Negative

Explore clinical trials studying Progesterone Receptor Negative. Study availability and eligibility vary by location and protocol.

33 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Progesterone Receptor Negative trial results

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT01281150

Conditions
Adult Solid Neoplasm, Breast Diseases, Breast Neoplasms, +16 more
Locations
  • Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States
  • UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +16 more
Locations
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
View all 1024 locations
View Trial Details
Active, Not Recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968

Conditions
Breast Adenocarcinoma, Breast Diseases, Breast Neoplasms, +17 more
Locations
  • St. Elizabeth Healthcare Edgewood, Kentucky, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University of Virginia Charlottesville, Virginia, United States
  • Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States
View Trial Details
Active, Not Recruiting

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

NCT02398773

Conditions
HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, +1 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 25 locations
View Trial Details
Active, Not Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT02488967

Conditions
Breast Adenocarcinoma, Breast Diseases, Breast Neoplasms, +14 more
Locations
  • Southern Cancer Center PC-Mobile Mobile, Alabama, United States
  • Southern Cancer Center PC-Providence Mobile, Alabama, United States
  • Southern Cancer Center PC-Springhill Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
View all 1296 locations
View Trial Details
Active, Not Recruiting

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

NCT02744053

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +8 more
Locations
  • Memorial Hermann Memorial City Medical Center Houston, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson in Katy Houston, Texas, United States
  • MD Anderson League City Nassau Bay, Texas, United States
View Trial Details

Related conditions